Companies Dominating the Liposome Drug Delivery Landscape
-
Companies Dominating the Liposome Drug Delivery Landscape
Companies in the liposome drug delivery market adopt strategies such as product innovation, focusing on targeted drug delivery, nanotechnology integration, and novel lipid formulations to enhance efficacy. They form strategic partnerships with pharma firms, research institutions, and CDMOs to accelerate development and commercialization. Some of these players include:
- Spectrum Pharmaceuticals, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Gilead Sciences, Inc.
- Celsion Corporation
- Ipsen Pharma
- Pacira Pharmaceuticals, Inc.
- Novartis AG
- CordenPharma International
- FUJIFILM Toyama Chemical Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Johnson & Johnson Services, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of grouting materials is assessed at USD 6.4 billion.
The liposome drug delivery market size was over USD 5.97 billion in 2024 and is anticipated to cross USD 18.52 billion by 2037, growing at more than 9.1% CAGR during the forecast period i.e., between 2025-2037. The rising prevalence of cancer globally, and the increasing application of liposomes as a drug delivery system will drive the market growth.
North America industry is anticipated to dominate majority revenue share of 45% by 2037, impelled by increasing prevalence of cancer in the region.
The major players in the market are Spectrum Pharmaceuticals, Inc., Gilead Sciences, Inc., Celsion Corporation, Ipsen Pharma, Pacira Pharmaceuticals, Inc., Novartis AG, CordenPharma International, FUJIFILM Toyama Chemical Co., Ltd., Takeda Pharmaceutical Company Limited, Johnson & Johnson Services, Inc.
